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Looking Back; Looking
Forward!ith this issue, Cellular and Molecular Gastroenter-W ology and Hepatology begins its second year of
publication. By any measure, tremendous progress has been
made toward establishing Cellular and Molecular Gastroen-
terology and Hepatology as a valuable resource for the
broader gastrointestinal research community.
By the numbers, our turnaround time from submission
to ﬁrst decision has remained at fewer than 21 days.
Examples of when a decision took longer than 28 days were
rare, and reﬂect our editorial philosophy of examining a
manuscript more deeply rather than taking the more
expedient route of rejecting articles with conﬂicting external
reviews or other complexities. This editorial philosophy
generalizes to treating authors as we would like to be
treated. Although not all submissions can be accepted for
publication, authors are entitled to serious consideration
and a fact-based, fair, and rational assessment of their work.
We have strived to explain our editorial decisions, particu-
larly if they were negative. Remarkably, this has led to re-
turn thank you letters in several cases. Although we never
expected such responses, we do genuinely hope that the
critiques provided will improve the work when it eventually
is published, even if it cannot be in Cellular and Molecular
Gastroenterology and Hepatology. This is another way in
which Cellular and Molecular Gastroenterology and Hep-
atology is expected to contribute to excellence in gastroin-
testinal research even beyond work that is presented in this
journal.
Overall, the Cellular and Molecular Gastroenterology and
Hepatology acceptance rate has been approximately 30%.
This value is somewhat inﬂated because preselection of fast-
track transfers from Gastroenterology has resulted in an
artiﬁcially increased acceptance rate. The acceptance rate
for direct submissions and those transferred from Gastro-
enterology by the standard (non–fast track) pathway is
approximately 20%. The Cellular and Molecular Gastroen-
terology and Hepatology site has had more than 70,000 page
views, 25,000 full-text views, and more than 15,000 unique
visitors; all of which attest to the high quality of the articles
published.
All basic and translational science submissions to
Gastroenterology may, at the authors’ request, be simply and
rapidly transferred to Cellular and Molecular Gastroenter-
ology and Hepatology. If a manuscript was reviewed exter-
nally at Gastroenterology, the reviews are transferred with
the submission by the fast-track process. The Board of
Editors releases a decision within 1 week (usually within afew days). If the decision is to invite a revision, the expec-
tations as to which changes are needed are described. When
a resubmission is received, it may be sent back to the
original external reviewers, new external reviewers, or
handled by the Board of Editors without external review,
depending on the extent of revision required. Manuscripts
transferred from Gastroenterology to Cellular and Molecular
Gastroenterology and Hepatology after rejection with inter-
nal review only are ﬁrst screened for scope. If they ﬁt within
the spectrum of Cellular and Molecular Gastroenterology and
Hepatology publications, these manuscripts generally then
are sent for external review by the standard process.
Nevertheless, the authors beneﬁt because the transfer is
simple and requires little effort on their part. There is no
need for reformatting, re-uploading, or any other work in
this process.
Finally, many have asked us whether we are indexed in
PubMed and when there will be an impact factor. With re-
gard to the former, we are not yet indexed in PubMed. The
request for indexing requires a minimum number of issues
and articles published. We have now surpassed the
threshold for early indexing and submitted our request
several months ago. When we are accepted, all articles
published in Cellular and Molecular Gastroenterology and
Hepatology will be indexed back to our ﬁrst issue. Until
then, Cellular and Molecular Gastroenterology and Hepatol-
ogy articles deposited in PubMed Central are available in
PubMed. We will not know our ﬁrst impact factor until June
2018. This is because 3 years of data (2015, 2016, and
2017) are required to calculate an impact factor and there is
then a lag until results are calculated and released. Despite
our interest in knowing the impact factor, we should make it
clear that we do not and will not consider citation impact
when evaluating manuscripts. Cellular and Molecular
Gastroenterology and Hepatology is sharply focused on
scientiﬁc impact and rigor.
JERROLD R. TURNER, MD, PhD, AGAF
Editor-in-ChiefCorrespondence
Address correspondence to: Jerrold R. Turner, MD, PhD, AGAF, Brigham and
Women’s Hospital, Boston, Massachusetts. e-mail: jrturner@partners.org.
Conﬂicts of interest
The author discloses no conﬂicts.
Most current article
© 2016 The Author. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2015.11.005Cellular and Molecular Gastroenterology and Hepatology 2016;2:1
